The stock price of Bioventus (BVS) has more than doubled in the past six months. This upside can be attributed to the encouraging sales performance across its business segments, based on which management raised the 2024 guidance twice this year. In the past six months, BVS stock significantly outperformed the industry's 5.1% rise. The stock has also outperformed the sector and the S&P 500 during the same period. BVS shares are also trading above the 50-day and 200-day moving averages. BVS Stock Outperforms ...

Bioventus (BVS) is a Zacks Rank #1 (Strong Buy) that has a C for Value and an A for Growth. This company makes drugs that help people heal quickly and safely. They target osteoarthritis, surgical and non surgical bones healing. Let's explore more about this company in this Bull of The Day article. Description Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculos ...

Bioventus Inc. (NASDAQ:BVS) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

DURHAM, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Wednesday, August 14, 2024, at 9:00 a.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioven ...

Financial Performance - Q2 2024 revenue reached $151.2 million, a 10.3% increase year-over-year, with organic growth of 13.9% driven by Pain Treatments and Surgical Solutions[2] - Adjusted EBITDA from continuing operations rose by 22.4% to $34.5 million, up from $28.2 million in the prior year[2] - The company reported a net loss from continuing operations of $32.1 million, compared to a loss of $4.7 million in the prior-year period, impacted by a non-cash impairment charge of $31.9 million[2] - Net sales for the three months ended June 29, 2024, were $151,217, an increase of 10.4% compared to $137,069 for the same period in 2023[10] - Gross profit for the six months ended June 29, 2024, was $192,019, up from $163,042 for the same period in 2023, reflecting a gross margin improvement[10] - The company reported a net loss from continuing operations of $32,112 for the three months ended June 29, 2024, compared to a loss of $4,731 for the same period in 2023[10] - Adjusted EBITDA for the three months ended June 29, 2024, was $34,452 thousand, an increase from $28,158 thousand in the same period last year, reflecting a growth of approximately 22%[19] - The net loss from continuing operations for the six months ended June 29, 2024 was $(38,094), resulting in an EPS of $(0.45)[24] Guidance and Future Outlook - Bioventus raised its full-year 2024 financial guidance, now expecting net sales of $557 million to $567 million, an increase of $19.5 million from previous guidance[4] - Adjusted EBITDA guidance for 2024 is now set at $104 million to $107 million, reflecting a $9 million increase from prior guidance[4] - Non-GAAP EPS guidance for 2024 is raised to $0.36 to $0.42, an increase of $0.10 from previous estimates[4] Operational Metrics - Gross margin expanded by 350 basis points, while adjusted gross margin improved by 180 basis points compared to the prior year[1] - Cash from operations increased by 40.5% to $15.2 million in Q2 2024[1] - Total current assets increased to $308,883 as of June 29, 2024, from $267,999 as of December 31, 2023, primarily driven by higher accounts receivable[9] - Total liabilities increased to $603,111 as of June 29, 2024, compared to $589,792 as of December 31, 2023, mainly due to an increase in current liabilities[9] - Cash and cash equivalents at the end of the period were $31,994, a decrease from $36,964 at the end of 2023[11] - The Company experienced a significant increase in interest expense, totaling $9,924 thousand for the three months ended June 29, 2024, compared to $10,587 thousand in the prior year[19] Strategic Initiatives - The company received FDA clearance for the OSTEOAMP Cannula, which is expected to enhance growth opportunities in the Minimally Invasive Spine Procedure market[4] - Bioventus is pursuing the divestiture of its Advanced Rehabilitation Business to reduce debt and focus on core operations[4] - The Company deconsolidated CartiHeal effective February 27, 2023, treating it as a discontinued operation, which may impact future financial reporting[16] Research and Development - Research and development expenses for the three months ended June 29, 2024, were $3,988, compared to $3,398 for the same period in 2023, indicating a focus on innovation[10] Non-GAAP Measures - Non-GAAP Gross Profit for the six months ended June 29, 2024, was $57,075 thousand, compared to $45,109 thousand for the same period in the prior year, indicating a year-over-year increase of about 26.5%[19] - Non-GAAP net income for the six months ended June 29, 2024 was $19,944, with an adjusted EPS of $0.25[24] - The Company emphasizes the importance of Non-GAAP measures for evaluating long-term performance trends and facilitating comparisons with peers[17] - The Company does not provide U.S. GAAP financial measures on a forward-looking basis due to uncertainties related to acquisitions and other reconciling items[17] Impairment Charges - The company incurred impairment of assets amounting to $31,870 during the three months ended June 29, 2024[10] - The company incurred significant impairment charges of $31,870 in both the three and six months ended June 29, 2024, impacting overall financial performance[24]

Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps Cash from Operations of $15.2 million Increased 40.5% Raising Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and si ...

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) on behalf of long-term stockholders following a class action complaint that was filed against Bioventus on January 12, 2023 with a Class Period pursuant to the February 11, 2021 IPO. Our investigation concerns whether the board of directors of Bioventus have breached their fiduciary duties to the company. Bioventu ...

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. About Bioventus Investor and Media Inquiries: Dave Crawford 919-474-6787 Dave.Crawford@bioventus.com DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, ...

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. About Bioventus Investor and Media Inquiries: Dave Crawford 919-474-6787 Dave.Crawford@bioventus.com DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, ...